Updates sits at the center of this dementia and brain health question.

The AD/PD 2026 Conference in Copenhagen delivered substantial clinical evidence for two leading Alzheimer’s disease treatments that could reshape how neurologists approach disease management. Blarcamesine demonstrated it can preserve nearly 18 months of cognitive function while protecting brain volume, while lecanemab showed that the majority of patients stay on treatment long-term—a crucial metric for real-world effectiveness. Together, these findings represent meaningful progress in slowing neurological decline in both Alzheimer’s disease and early Parkinson’s disease, marking a shift from symptomatic treatment to disease-modifying approaches backed by measurable outcomes.

The significance of these updates lies not just in efficacy but in how they translate to clinical practice and patient outcomes. The conference, held March 17-21, 2026, presented data that addresses long-standing questions about whether these therapies sustain their benefits beyond the initial treatment window and whether they work better in certain patient populations. This article covers the key findings from both compounds, what the brain imaging data tells us, and what these regulatory approvals mean for patients and caregivers navigating Alzheimer’s disease today.

What Did Blarcamesine Show About Slowing Alzheimer’s Disease?
How Does Blarcamesine Work Better in Some Patients Than Others?
Did Blarcamesine Show Benefits for Parkinson’s Disease?
What Do Lecanemab’s Real-World Treatment Persistence Numbers Actually Mean?
How Does Lecanemab’s Mechanism Differ From Other Anti-Amyloid Approaches?
What Are the New Regulatory Milestones for Lecanemab?
What Does This Conference Data Mean for Clinical Practice Going Forward?
Conclusion

What Did Blarcamesine Show About Slowing Alzheimer’s Disease?

Blarcamesine, developed by anavex Life Sciences, presented Phase IIb/III trial results from the AD-004 study showing that oral treatment saved 77.4 weeks—nearly 18 months—of disease progression in Alzheimer’s patients after 144 weeks of continuous treatment. This figure comes from clinical decline measures, not just statistical projections. To put this in concrete terms: a patient experiencing typical Alzheimer’s decline might progress from early cognitive changes to requiring assistance with daily activities over a certain timeline. Blarcamesine lengthened that timeline by over a year, meaning patients maintained greater independence and cognitive function for substantially longer.

Beyond the clinical measures, brain MRI imaging showed structural benefits. The treatment preserved brain volume in regions critical to memory and cognition, and these volumetric changes correlated directly with the functional improvements patients experienced. This correlation matters because it demonstrates the drug isn’t just masking symptoms—it’s preserving the actual brain tissue that cognition depends on. This represents a shift from earlier Alzheimer’s drugs that slowed decline by modest percentages; blarcamesine’s 77-week benefit approaches doubling the time before significant functional deterioration.

What Did Blarcamesine Show About Slowing Alzheimer's Disease?

How Does Blarcamesine Work Better in Some Patients Than Others?

One of the most clinically relevant findings from the AD-004 trial involves precision medicine. Researchers stratified patients by genetic status and found that those carrying wild-type versions of the SIGMAR1 and COL24A1 genes showed substantially enhanced clinical and structural responses to blarcamesine. This genotype-stratified benefit suggests that future prescribing might benefit from genetic testing before initiating therapy—patients with these genetic profiles could potentially see greater benefit, while those without them might receive less noticeable improvements.

However, the clinical application of genotype testing remains in early stages. While the data supports a biological mechanism linking these genes to blarcamesine’s action, not all clinicians have ready access to genetic testing, and insurance coverage for such testing remains inconsistent. Additionally, the trial included relatively healthy, carefully monitored patients—the “real world” effectiveness in diverse populations with comorbidities and medication interactions still needs documentation. This gap between clinical trial precision and everyday practice means that genotype-guided therapy likely won’t become standard immediately, but it establishes the rationale for pursuing such approaches as testing becomes more accessible.

Did Blarcamesine Show Benefits for Parkinson’s Disease?

Beyond Alzheimer’s work, blarcamesine showed promising activity in Parkinson’s disease using a preclinical alpha-synuclein model presented at the March 17, 2026 session. The key finding was dopaminergic nerve fiber regrowth in the striatum—the brain region critical for movement control—detected after just 6 weeks of treatment using specialized biomarkers measuring nerve fiber density. Parkinson’s disease involves the progressive loss of dopamine-producing neurons, so evidence of fiber regrowth rather than just slowed decline represents a conceptual advance.

The treatment also produced significant effects on motor function measures in the alpha-synuclein model, suggesting benefits beyond neuroprotection. However, these results come from preclinical work (animal or cell-based models), not yet from human trials. The leap from a preclinical Parkinson’s model to human efficacy and safety data will require properly conducted clinical trials; the alpha-synuclein model represents proof of concept, not proof of human benefit. That said, the specificity of the finding—dopaminergic fiber regrowth rather than vague “neuroprotection”—suggests that blarcamesine’s mechanism genuinely engages relevant biology in Parkinson’s pathology.

Did Blarcamesine Show Benefits for Parkinson's Disease?

What Do Lecanemab’s Real-World Treatment Persistence Numbers Actually Mean?

Lecanemab (marketed as LEQEMBI) presented real-world data on how long patients remain on treatment, and the numbers reveal a crucial gap between clinical trials and actual practice. In the real world, 78.4% of patients continued treatment at 18 months, 71.7% at 20 months, and 67.3% at 24 months. These figures represent the first long-term real-world persistence data for lecanemab beyond the initial 18-month trial period. Compared to many other Alzheimer’s drugs where persistence drops sharply after 12-18 months due to infusion burden, side effects, or perceived lack of benefit, these retention rates suggest lecanemab has a reasonable tolerability and perceived benefit profile.

Why this matters: persistence directly impacts public health benefit. A drug that cures disease but only works if patients stay on it for years can’t fulfill its promise if people stop. The 67.3% persistence at 24 months indicates that roughly two-thirds of patients who start lecanemab continue the treatment journey beyond two years—a meaningful proportion, though not universal. The gap between 18-month (78%) and 24-month (67%) persistence represents real reasons patients discontinue: some experience infusion-related side effects (amyloid-related imaging abnormalities, or ARIA), others face logistical challenges with biweekly infusions, and some may question whether the modest slowing of decline justifies the burden. The data doesn’t reveal which reason dominates, limiting actionability for clinicians counseling new patients.

How Does Lecanemab’s Mechanism Differ From Other Anti-Amyloid Approaches?

Lecanemab selectively targets soluble amyloid-beta protofibrils—a specific form of the amyloid protein that accumulates in Alzheimer’s disease. Rather than targeting mature amyloid plaques, this precision targeting aims at earlier aggregation forms thought to be particularly toxic to neurons. Once bound, lecanemab engages immune system pathways to promote clearance of these protein aggregates, essentially marking them for removal by the brain’s cleanup mechanisms. This specificity represents an intentional design choice.

Earlier amyloid-targeting approaches sometimes caused excessive immune activation and inflammation (ARIA), while lecanemab’s focus on protofibrils may reduce this risk. However, the real-world persistence data showed that some patients still discontinued due to imaging abnormalities, suggesting that even this refined approach doesn’t entirely eliminate immunological risks. Clinicians must screen for contraindications like severe cerebrovascular disease before initiating treatment, and patients require regular MRI monitoring to detect asymptomatic amyloid-related imaging abnormalities. These monitoring requirements add to the burden of treatment compared to oral therapies like blarcamesine.

How Does Lecanemab's Mechanism Differ From Other Anti-Amyloid Approaches?

What Are the New Regulatory Milestones for Lecanemab?

Lecanemab achieved FDA Priority Review status in January 2026 for a subcutaneous starting-dose formulation, with an anticipated PDUFA date of May 24, 2026. Additionally, the compound received Priority Review designation in China in February 2026 for the same subcutaneous formulation. These regulatory pathways matter because subcutaneous administration could substantially reduce the treatment burden compared to current biweekly intravenous infusions, potentially improving both persistence and accessibility. The significance of subcutaneous formulation extends beyond convenience.

IV infusions require clinic visits, trained staff for administration, and immediate access to emergency services if infusion reactions occur. Subcutaneous dosing could shift treatment toward outpatient, more accessible settings—though it remains far simpler than oral therapy. The May 2026 PDUFA date means regulatory decisions are imminent, and the approval timeline will determine when this formulation reaches patients. Chinese approval pathways matter globally because China represents a massive Alzheimer’s population and market expansion; successful implementation there could inform regulatory confidence elsewhere and potentially affect global pricing and manufacturing.

What Does This Conference Data Mean for Clinical Practice Going Forward?

The converging evidence from these two compounds suggests a future where Alzheimer’s disease treatment becomes more stratified and precise. Blarcamesine’s genotype-stratified benefits point toward genetic testing as part of baseline evaluation; lecanemab’s subcutaneous formulation could expand accessibility; and together, these findings validate the disease-modifying approach rather than symptomatic treatment alone. Clinicians who attend AD/PD 2026 education sessions will likely accelerate adoption based on the magnitude of clinical benefits presented.

The remaining uncertainties should temper optimism. Blarcamesine’s FDA approval timeline remains undecided—the brain volume and functional preservation are compelling, but regulatory authorities may request additional safety or efficacy data before approval. Lecanemab’s real-world data, while encouraging about persistence, still shows meaningful discontinuation rates (32.7% by month 24), indicating the therapy is far from universally tolerated or effective. The conference presents proof of concept, not necessarily the final word on how these treatments will perform across diverse, real-world populations.

Conclusion

The AD/PD 2026 Conference in Copenhagen provided substantial clinical evidence that anti-Alzheimer’s treatments are advancing toward meaningful disease modification. Blarcamesine demonstrated the capacity to preserve nearly 18 months of cognitive function and brain volume while showing early promise in Parkinson’s disease models, supported by potential genotype-guided therapy that could identify patients most likely to benefit. Lecanemab’s long-term real-world persistence data—with two-thirds of patients continuing at 24 months—establishes the practical feasibility of a disease-modifying monoclonal antibody approach, while its upcoming subcutaneous formulation could dramatically expand accessibility.

For patients and families facing Alzheimer’s disease, these updates represent expanded options and improving evidence that treatments can work if matched carefully to individual biology and circumstances. The next practical step involves waiting for regulatory decisions (particularly the May 2026 LEQEMBI subcutaneous PDUFA date) and discussing with neurology specialists whether genotype testing, amyloid biomarkers, or imaging might help identify which therapy suits an individual’s profile best. The field is moving from “accept decline” to “choose your intervention strategy”—a fundamental shift that requires informed, shared decision-making between patients, families, and clinicians.